Jyong Bio (MENS) - Long-Term Debt to Capital Coefficient

Jyong Bio - graphic logo of issuer MENS

The daily price chart for Jyong Biotech Ltd (MENS) shows a figure of 0.00, a critical factor when analyzing the business's dependence on external manufacturing contractors. The Taiwanese company generates revenue from the creation of urological products, utilizing a licensing model to minimize capital expenditures. The brand's innovative image in botanical medicine helps the firm attract capital and the trust of specialists.

Jyong Biotech Limited (MENS): Long-Term Debt to Equity from 06/18/2025 to 10/31/2026

Comprehensive metric breakdowns and analytics for Jyong Biotech Ltd (MENS)

- stock price and consensus target price:
Quote Chart Jyong Biotech Limited|MENS - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Jyong Biotech Ltd|MENS - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Jyong Biotech|MENS - Company Book Value|Market Value to Book Value jyongbio.com|MENS - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Jyong Biotech Ltd|MENS - Long-Term Debt to Capital|Short-Term Debt to Capital jyongbio.com|MENS - Company Total Debt|Debt to Net Assets Ratio Jyong Biotech Ltd|MENS - Company Long-Term Debt|Short-Term Debt Jyong Biotech|Intermediate Liquidity Ratio jyongbio.com
- net income and valuation ratios data:
MENS - Net Profit
General company analysis:Jyong Biotech Limited - MENS
Signature product of Jyong Biotech Ltd

Funding advanced laboratories and retaining highly qualified biologists at Jyong Biotech Ltd (MENS) requires significant long-term infrastructure investments. By analyzing the long-term debt-to-equity ratio, an investor assesses the proportion of liabilities with maturities exceeding one year relative to equity, which determines the company's level of dependence on external borrowings and the overall stability of its financial foundation.

Analysis of competing companies

Haleon PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital KVUE|VRNA (Verona Pharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital LGND (Ligand Pharmaceuticals)|Long-Term Debt to Capital amneal.com AMRX|PRGO - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient ALVO (Alvotech S.A.)|Liquidia Technologies (LQDA) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Galapagos Corp|ANIP (ANI Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital mannkindcorp.com|Long-Term Debt to Equity Ratio AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Pharmaceuticals) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity ARS Pharma SPRY|Theravance Corp (TBPH) - Long-Term Liabilities to Capital|AQST: Long-Term Debt to Equity Ratio|scPharmaceuticals Inc. - Long-Term Loans to Capital Ratio|TECX: Long-Term Debt to Capital|Tonix Pharma - Long-Term Debt to Capital Coefficient|SXTC (SXT Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Eupraxia Pharma EPRX|Long-Term Debt to Equity BioHarvest Sciences (BHST)|EXOZ (invizyne.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Oramed Pharmaceuticals Inc. ORMP|Long-Term Loans to Capital Ratio ENTX (Entera Bio Ltd)|HYFT: Long-Term Debt to Equity Ratio|Long-Term Liabilities to Capital ABVC BioPharma, Inc|Cumberland Pharmaceuticals (CPIX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital quantumbiopharma.com (QNTM)|Long-Term Debt to Equity FibroGen|Long-Term Debt to Capital Ratio TELO (Telomir Pharmaceuticals Inc)|Long-Term Debt to Capital RANI|synergychc.com (SNYR) - Long-Term Indebtedness to Equity|Rallybio - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient LEXX|Pulmatrix - Long-Term Debt to Capital|PTHL: Long-Term Debt to Equity|APM: Long-Term Debt to Capital|LYRA - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Impact BioMedical Inc|Long-Term Liabilities to Capital TNF Pharma TNFA|Long-Term Debt to Equity Ratio YCBD (cbdMD, Inc.)|Long-Term Loans to Capital Ratio PRFX|Long-Term Debt to Capital CYTO (Altamira Therapeutics Ltd.)|Lipella Pharma (LIPO) - Long-Term Liabilities to Capital|OptiNose, Inc. - Long-Term Debt to Capital|pieris.com (PIRS) - Long-Term Debt to Equity Ratio|PROC: Long-Term Debt to Capital|Petros Pharmaceuticals Inc - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio QLI|SLRN: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity TFF Pharmaceuticals (TFFP)